Cortoss enters kyphoplasty trial in US:
This article was originally published in Clinica
Executive Summary
Orthovita is to begin a second pilot clinical study to evaluate its Cortoss synthetic cortical bone void filler in the treatment of vertebral compression fractures (VCF) using a treatment technique called kyphoplasty. During kyphoplasty, an inflatable bone tamp is used to reduce the fracture and create a void in which the CORTOSS biomaterial can be injected. In January 2003, Orthovita began its first US pilot clinical study of CORTOSS for treating VCF using the vertebroplasty technique, whereby the biomaterial is injected without using the inflatable device. In the same month, the Malvern, Pennsylvania firm gained European approval to market the product for vertebral augmentation, including the repair of VCF.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.